EHMT2 and familial pancreatic carcinoma: Additionally, we tested the impact of EHMT2 inhibition on NK cell-mediated pancreatic cancer eradication, which is another cancer type for which adaptive immune checkpoint blockade therapies have not worked as desired (Royal et al, 2010).